ProStrakan Group Plc Oct. 1 announced that it has entered into an agreement with GTx Inc. to acquire the exclusive U.S. commercial rights to Fareston (toremifene citrate).
Fareston is a selective estrogen receptor modulator indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors.
Prostrakan said it has paid GTx a lump sum of $21.7 million to acquire the U.S. rights to Fareston and related assets.
Under the agreement, Orion Corp., the company that developed toremifene, will continue to manufacture and supply Fareston for the U.S. market under an exclusive license and supply ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.